Literature DB >> 8712922

Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients.

J Li1, L B Zhang, T Yoneyama, H Yoshida, H Shimizu, K Yoshii, M Hara, T Nomura, H Yoshikura, T Miyamura, A Hagiwara.   

Abstract

We examined four type 1 polioviruses isolated from the stools of patients with vaccine-associated paralytic poliomyelitis in China. All of these isolates were shown to be Sabin derived viruses by restriction fragment length polymorphism assay after polymerase chain reaction and by sequencing of the viral genome encoding the viral coat protein, VP1. However, the same analysis of the 3D coding region suggested that two of the four isolates had the sequence of wild type poliovirus in the tested region. Furthermore there were also point mutations in the 5' non-coding region. One was a single base change from U to C at nucleotide position 525, and the other three were from G to A at position 480. All the four strains were more neurovirulent that Sabin type 1 virus in transgenic mice with human poliovirus receptor gene. The data showed that the nucleotide positions of type 1 poliovirus which were identified to be in favor of the high neurovirulence were indeed changed during natural transmission, and suggested that the point mutation alone or a recombination of the vaccine type with wild type genome results in an acquisition of neurovirulence.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8712922     DOI: 10.1007/BF01718608

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  12 in total

1.  Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases.

Authors:  G Y Lipskaya; A R Muzychenko; O K Kutitova; S V Maslova; M Equestre; S G Drozdov; R P Bercoff; V I Agol
Journal:  J Med Virol       Date:  1991-12       Impact factor: 2.327

2.  The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay.

Authors:  J Balanant; S Guillot; A Candrea; F Delpeyroux; R Crainic
Journal:  Virology       Date:  1991-10       Impact factor: 3.616

3.  Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.

Authors:  K M Chumakov; L B Powers; K E Noonan; I B Roninson; I S Levenbook
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

4.  Genetic analysis of wild-type 1 poliovirus isolates in China, 1985-1993.

Authors:  J Li; T Yoneyama; H Yoshida; K Yoshii; H Shimizu; T Miyamura; M Hara; X H Hou; H Zheng; Y Fang
Journal:  Res Virol       Date:  1995 Nov-Dec

5.  Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature.

Authors:  C Christodoulou; F Colbere-Garapin; A Macadam; L F Taffs; S Marsden; P Minor; F Horaud
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

Review 6.  [Planned production of poliovirus-sensitive transgenic mice].

Authors:  K Hioki; H Katoh; S Endo; M Saito; T Nomura
Journal:  Jikken Dobutsu       Date:  1993-07

7.  Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis.

Authors:  M Furione; S Guillot; D Otelea; J Balanant; A Candrea; R Crainic
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

8.  Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction.

Authors:  S Guillot; D Otelea; F Delpeyroux; R Crainic
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

9.  Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984.

Authors:  B M Nkowane; S G Wassilak; W A Orenstein; K J Bart; L B Schonberger; A R Hinman; O M Kew
Journal:  JAMA       Date:  1987-03-13       Impact factor: 56.272

10.  Transgenic mice susceptible to poliovirus.

Authors:  S Koike; C Taya; T Kurata; S Abe; I Ise; H Yonekawa; A Nomoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

View more
  15 in total

1.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

2.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 5.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

7.  Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications.

Authors:  A Georgopoulou; P Markoulatos; N Spyrou; N C Vamvakopoulos
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

8.  Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient.

Authors:  Chen-Fu Yang; Hour-Young Chen; Jaume Jorba; Hui-Chih Sun; Su-Ju Yang; Hsiang-Chi Lee; Yhu-Chering Huang; Tzou-Yien Lin; Pei-Jer Chen; Hiroyuki Shimizu; Yorihiro Nishimura; Andi Utama; Mark Pallansch; Tatsuo Miyamura; Olen Kew; Jyh-Yuan Yang
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

9.  Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China.

Authors:  Hong-Mei Liu; Du-Ping Zheng; Li-Bi Zhang; M Steven Oberste; Olen M Kew; Mark A Pallansch
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Changes in population dynamics during long-term evolution of sabin type 1 poliovirus in an immunodeficient patient.

Authors:  John K Odoom; Zaira Yunus; Glynis Dunn; Philip D Minor; Javier Martín
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.